Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
1,84 SEK | -0,97% | +2,22% | -54,11% |
Métier
Nombre d'employés: 23
Ventes par activité
SEK en Millions | 2021 | Poids | 2022 | Poids | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100,0
%
| 10 | 100,0 % | 15 | 100,0 % | +45,86% |
Ventes par région
SEK en Millions | 2021 | Poids | 2022 | Poids | Delta |
---|---|---|---|---|---|
Other European Countries
75,4
%
| 8 | 76,1 % | 12 | 75,4 % | +44,49% |
Americas
24,6
%
| 3 | 23,9 % | 4 | 24,6 % | +50,16% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Founder | 66 | 01/01/11 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 01/01/11 |
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 01/01/14 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 01/05/20 | |
Corporate Officer/Principal | 52 | - |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Director/Board Member | 66 | 01/01/15 | |
Anna Ljung
BRD | Director/Board Member | 44 | 19/01/18 |
Director/Board Member | 58 | 01/01/23 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 132 529 086 | 80 887 377 ( 61,03 %) | 0 | 61,03 % |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Secteur
Ventes par région
Bénéfices annuels - Taux de surprise
Varia. 1 janv. | Capi. | |
---|---|---|
-54,11% | 18,85 M | |
-2,83% | 103 Md | |
+1,56% | 95,28 Md | |
+1,46% | 22,15 Md | |
-16,21% | 21,02 Md | |
-8,58% | 18,15 Md | |
-38,74% | 16,73 Md | |
-13,13% | 16,05 Md | |
+5,57% | 13,68 Md | |
+33,30% | 12,17 Md |
- Bourse
- Actions
- Action SANION
- Société SANA AB